Impact of aryloxy-linked quinazolines: A novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors
- 1 April 2011
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (7), 2106-2112
- https://doi.org/10.1016/j.bmcl.2011.01.137
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- VEGFs and receptors involved in angiogenesis versus lymphangiogenesisCurrent Opinion in Cell Biology, 2009
- Vascular endothelial growth factor receptors: Molecular mechanisms of activation and therapeutic potentialsExperimental Eye Research, 2006
- Angiogenesis—a new target for future therapyVascular Pharmacology, 2006
- The ErbB/HER receptor protein-tyrosine kinases and cancerBiochemical and Biophysical Research Communications, 2004
- Angiogenesis in health and diseaseNature Medicine, 2003
- Protein Kinase Inhibitors as a Therapeutic ModalityAccounts of Chemical Research, 2003
- Protein kinases — the major drug targets of the twenty-first century?Nature Reviews Drug Discovery, 2002
- Receptor tyrosine kinases as targets for anticancer drugsTrends in Molecular Medicine, 2002
- Tyrosine kinase inhibitors: From rational design to clinical trialsMedicinal Research Reviews, 2001
- The role of protein phosphorylation in human health and disease.JBIC Journal of Biological Inorganic Chemistry, 2001